Performance of the serologic and molecular screening of blood donations for the hepatitis B and C viruses in a Mexican Transfusion Center

Nucleic acid-amplification testing (NAT) is not routinely practiced in blood banks from most low-income countries. We did an exploratory comparison of the performance of the standard immunoassay-based screening tests for the hepatitis B (HBV) and C (HCV) viruses with that of NAT, in blood donors. Fr...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hepatology 2005-10, Vol.4 (4), p.275-278
Main Authors: Chiquete, Erwin, Sánchez, Laura V, Becerra, Guadalupe, Quintero, Angeles, Maldonado, Montserrat, Panduro, Arturo
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Blood bank
Blood Banks
Blood Donors
DNA, Viral - blood
epidemiology
Hepacivirus - isolation & purification
hepatitis B
Hepatitis B - epidemiology
Hepatitis B Antibodies - blood
Hepatitis B virus - isolation & purification
hepatitis C
Hepatitis C - epidemiology
Hepatitis C Antibodies - blood
Humans
Immunoenzyme Techniques
liver
Mexico
Middle Aged
Polymerase Chain Reaction
Reproducibility of Results
RNA, Viral - blood
Seroepidemiologic Studies
serology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nucleic acid-amplification testing (NAT) is not routinely practiced in blood banks from most low-income countries. We did an exploratory comparison of the performance of the standard immunoassay-based screening tests for the hepatitis B (HBV) and C (HCV) viruses with that of NAT, in blood donors. From January 1999 to March 2005, 94,806 blood donors were screened for anti-HCV antibodies and for hepatitis B surface antigen (HBsAg). Also, an exploratory period of molecular screening was carried out on 100 consecutive blood donors to detect HBV DNA and HCV RNA by home-made PCR techniques without sera pooling. In the 75-month period of serologic screening, HBsAg was detected in 219 donors (0.23%; 95% CI, 0.20- 0.26%) and anti-HCV antibodies in 922 (0.97%; 95% CI, 0.90-1.03%). The annual trend for HBsAg prevalence had a decreasing pattern over the years (p
ISSN:1665-2681
DOI:10.1016/s1665-2681(19)32052-6